Table 3.
Univariate and multivariate Cox regression analysis of overall survival in lung cancer patients
| Variables | Univariate analysis
|
Multivariate analysis
|
||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Sex (male vs female) | 1.115 (0.584–2.131) | 0.741 | ||
| Age | 1.032 (1.002–1.063) | 0.038* | 1.049 (1.014–1.085) | 0.006* |
| Histological grade (I+II vs III) | 0.607 (0.286–1.288) | 0.194 | ||
| TNM stage (I+II vs III+IV) | 0.235 (0.115–0.479) | 0.000* | 0.190 (0.086–0.418) | 0.000* |
| ALK (negative vs positive) | 1.913 (0.586–6.243) | 0.282 | ||
| EGFR (negative vs positive) | 0.682 (0.356–1.308) | 0.250 | ||
| Survivin (negative vs positive) | 0.756 (0.374–1.531) | 0.437 | ||
| VEGF (negative vs positive) | 0.702 (0.340–1.450) | 0.339 | ||
| SIRT1 (negative vs positive) | 0.251 (0.089–0.709) | 0.009* | 0.347 (0.103–1.167) | 0.087 |
Note:
*
indicates statistical significance.
Abbreviations: HR, hazard ratio; CI, confidence interval; TNM, tumor–node–metastasis; ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor; SIRT1, silent mating-type information regulation 2 homolog 1.